- Home
- / Mersana Therapeutics
Mersana Therapeutics
Stock Price
$1.9
2024-10-29
Market Capitalization
$250.3 M
2024-10-28
Revenue
$40.5 M
FY, 2024
Mersana Therapeutics Summary
Company Summary
- Overview
- Mersana Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) platforms. It engineers immunoconjugate therapies and the DolaLock Technology, Dolaflexin, Dolasynthen, and Immunosynthen pipelines and platforms to deliver payloads of anti-tumor agents directly to cancerous cells.
- Type
- Public
- Status
- Active
- Founded
- 2005
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://www.mersana.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Arvin Yang, Senior Vice President and Chief Medical Officer
Mohan Bala, Senior Vice President, Strategic Product Planning & Program Leadership
Michael Kaufman, Chief Manufacturing Officer
Operating MetricsView all
Patents (US)
7
Apr, 2017
Patents Pending (US)
10
Apr, 2017
LocationsView all
1 location detected
Cambridge, MA HQ
United States
840 Memorial Dr
Mersana Therapeutics Financials
Summary Financials
- Revenue (Q3, 2025)
- $11.0M
- Net income (Q3, 2025)
- ($7.5M)
- Cash (Q3, 2025)
- $56.4M
- Enterprise value
- $196.1M